UPDATED
ACTC selects two drugs for Alzheimer’s for clinical trials
Japanese pharmaceutical company Eisai sends two new Alzheimer’s prevention drugs into the clinic after ACTC selection.
Archives for May 14, 2019
Bayer invests $150m to expand its biologics development
Bayer will build a 40,000-square-foot cell culture facility to bolster its capacity to develop therapies primarily focused on oncology and cardiology.
Merger looks to create bacteriophages to counter antibiotic resistance
AmpliPhi Biosciences and C3J Therapeutics merge to focus on the development of phage-based therapeutic candidates for antibiotic resistance.